Switch theme
Sign up to access all valuation multiples
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
2010
143
LTM Revenue $14.5M
Last FY EBITDA -$27.6M
$10.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
X4 Pharmaceuticals has a last 12-month revenue (LTM) of $14.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, X4 Pharmaceuticals achieved revenue of $2.6M and an EBITDA of -$27.6M.
X4 Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See X4 Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $14.5M | XXX | $2.6M | XXX | XXX | XXX |
| Gross Profit | $11.3M | XXX | $1.8M | XXX | XXX | XXX |
| Gross Margin | 78% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$27.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1078% | XXX | XXX | XXX |
| EBIT | -$77.7M | XXX | -$141M | XXX | XXX | XXX |
| EBIT Margin | -537% | XXX | -5530% | XXX | XXX | XXX |
| Net Profit | -$56.9M | XXX | -$37.5M | XXX | XXX | XXX |
| Net Margin | -393% | XXX | -1465% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $19.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, X4 Pharmaceuticals's stock price is $3.
X4 Pharmaceuticals has current market cap of $19.8M, and EV of $10.9M.
See X4 Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10.9M | $19.8M | XXX | XXX | XXX | XXX | $-7.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, X4 Pharmaceuticals has market cap of $19.8M and EV of $10.9M.
X4 Pharmaceuticals's trades at 4.2x EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate X4 Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
X4 Pharmaceuticals has a P/E ratio of -0.3x.
See valuation multiples for X4 Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.8M | XXX | $19.8M | XXX | XXX | XXX |
| EV (current) | $10.9M | XXX | $10.9M | XXX | XXX | XXX |
| EV/Revenue | 0.8x | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.1x | XXX | -0.1x | XXX | XXX | XXX |
| EV/Gross Profit | 1.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.3x | XXX | -0.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialX4 Pharmaceuticals's last 12 month revenue growth is 97%
X4 Pharmaceuticals's revenue per employee in the last FY averaged $18K, while opex per employee averaged $1.0M for the same period.
X4 Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
X4 Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for X4 Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 97% | XXX | 209% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -1078% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -981% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $18K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3193% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 5599% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
X4 Pharmaceuticals acquired XXX companies to date.
Last acquisition by X4 Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . X4 Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was X4 Pharmaceuticals founded? | X4 Pharmaceuticals was founded in 2010. |
| Where is X4 Pharmaceuticals headquartered? | X4 Pharmaceuticals is headquartered in United States of America. |
| How many employees does X4 Pharmaceuticals have? | As of today, X4 Pharmaceuticals has 143 employees. |
| Who is the CEO of X4 Pharmaceuticals? | X4 Pharmaceuticals's CEO is Dr. Paula S. Ragan, PhD. |
| Is X4 Pharmaceuticals publicy listed? | Yes, X4 Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of X4 Pharmaceuticals? | X4 Pharmaceuticals trades under XFOR ticker. |
| When did X4 Pharmaceuticals go public? | X4 Pharmaceuticals went public in 2017. |
| Who are competitors of X4 Pharmaceuticals? | Similar companies to X4 Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of X4 Pharmaceuticals? | X4 Pharmaceuticals's current market cap is $19.8M |
| What is the current revenue of X4 Pharmaceuticals? | X4 Pharmaceuticals's last 12 months revenue is $14.5M. |
| What is the current revenue growth of X4 Pharmaceuticals? | X4 Pharmaceuticals revenue growth (NTM/LTM) is 97%. |
| What is the current EV/Revenue multiple of X4 Pharmaceuticals? | Current revenue multiple of X4 Pharmaceuticals is 0.8x. |
| Is X4 Pharmaceuticals profitable? | Yes, X4 Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
